Overview

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).

Status:
Active, not recruiting

Trial end date:
2021-10-29

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Antineoplastic Agents
Carboplatin
Cisplatin
Durvalumab
Gemcitabine
Paclitaxel
Pemetrexed
Tremelimumab